What You Should Know:
– ConcertAI, a developer of AI-powered healthcare solutions, announced today the acquisition of CancerLinQ, a subsidiary of the American Society of Clinical Oncology (ASCO).
– This strategic move will significantly enhance and expand CancerLinQ’s capabilities, unlocking the potential of real-world data and next-generation AI to revolutionize cancer care and accelerate clinical research.
CancerLinQ Background
CancerLinQ represents one of the largest oncology real-world data and quality of care technology services entities in the world. With access to data from nearly seven million patients across a network of over 100 cancer centers and oncology practices, CancerLinQ empowers healthcare professionals with data-driven insights to improve care delivery and research outcomes.
CancerLinQ Acquisition Benefits
Building on CancerLinQ’s existing strengths, the acquisition will:
– Expand CancerLinQ’s real-world data platform: ConcertAI will invest more than $250 million over the next few years to integrate additional data sources into the platform, providing a broader and deeper understanding of cancer patients and their care.
– Develop innovative clinical trial solutions: By leveraging ConcertAI’s Digital Access to Clinical Trial (DACT) platform, CancerLinQ will facilitate patient participation in clinical trials, making it more accessible and less burdensome.
– Enhance clinical decision support tools: The combined expertise of ConcertAI and ASCO will lead to the development of more robust clinical decision support tools within the SmartLinQ™ platform, empowering physicians to make informed treatment decisions.
– Streamline data integration: Automated EMR integration will be implemented, seamlessly incorporating SmartLinQ into existing practice workflows.
This collaboration is expected to deliver significant benefits for various stakeholders:
– Oncology practices: Enhanced SmartLinQ™ platform, improved access to clinical trials, and streamlined data integration.
– Patients: Better access to treatment options, improved care quality, and more personalized treatment plans.
– Researchers: Faster development of new drugs and therapies through access to a vast and diverse pool of real-world data.
“We believe this agreement will provide the resources to fulfill and amplify CancerLinQ’s impact,” said Dr. Clifford A. Hudis, MD, FACP, FASCO, Chief Executive Officer of ASCO. “We expect CancerLinQ to be an important avenue for practices to achieve certification under ASCO’s recently launched ASCO Certified program.”
